A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia.

Trial Profile

A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Aripiprazole (Primary) ; Aripiprazole (Primary) ; Paliperidone; Paliperidone
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms QUALIFY
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2017 Resultsb of a post-hoc analysis evaluating the differential treatment effects of Aripiprazole once-monthly 400 mg (AOM 400) and paliperidone palmitate (PP) on sexual dysfunction and prolactin levels, published in the International Clinical Psychopharmacology.
    • 08 Dec 2016 Results published in the International Journal of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top